• SRX Global announced UC Davis as a new site for CERo Therapeutics’ ongoing Phase 1 CERTAIN-T trial of CER-1236 in blood cancers.
• UC Davis already manufactures CER-1236; adding patient enrollment is expected to expand recruitment capacity and streamline treatment logistics.
• Previously reported preliminary results showed clinical improvement in two patients, with no dose-limiting toxicities or treatment-related severe adverse events during assessment.
• The findings remain insufficient to establish safety or efficacy; formal response assessments were ongoing.
• The expansion follows an October 7, 2026, agreement to acquire CERo Therapeutics, subject to customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SRX Global Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260905PRIMZONEFULLFEED9852192) on October 26, 2026, and is solely responsible for the information contained therein.